A research lab in Australia has announced that it will begin phase one testing for a COVID-19 vaccine, the third such trial in the world.
The Phase I trial of the NVX-CoV2373 vaccine will begin at Nucleus’ Melbourne and Brisbane clinics in mid-May. The preliminary immunogenicity and safety results from the study are expected to be available in July.
Nucleus Network CEO Cameron Johnson said: “Nucleus has a rich history of Phase I vaccine trials, and a long-standing track-record with Novavax. We are well positioned to implement rapid testing with first-in-human trials over the coming weeks."
Previously, Novavax worked on vaccines for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).
Scientists all around the world are grappling to find a vaccine for the novel virus which appeared in China last December and has since killed over 145,551 people globally and infected 2,182,823 others.
